US EditionThe impact of lipid compositions on siRNA and mRNA lipid nanoparticle performance for pulmonary delivery - Pharma Excipients
Summary by Pharma Excipients
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
The impact of lipid compositions on siRNA and mRNA lipid nanoparticle performance for pulmonary delivery - Pharma Excipients
Abstract Lipid nanoparticles (LNPs) are of significant interest as delivery systems for various RNA therapeutics, not least due to their outstanding success in applications including the COVID-19 vaccines and the siRNA therapeutic Onpattro®. As LNPs consist of different lipids, the lipid composition determines key properties of these particles. This study examines how lipid composition, especially helper and PEG-lipids, and RNA cargo (siRNA and …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
